

Resource Summary Report

Generated by [RRID](#) on Aug 10, 2026

Rabbit Anti-Human Her2 / ErbB2 Monoclonal Antibody, Unconjugated, Clone 29D8

RRID:AB_10692490

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2165, RRID:AB_10692490

Antibody Information

URL: http://antibodyregistry.org/AB_10692490

Proper Citation: Cell Signaling Technology Cat# 2165, RRID:AB_10692490

Target Antigen: Human Her2 / ErbB2

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P, IHC-F, IF-IC, F. Consolidation on 11/2018: AB_10692490, AB_10831814, AB_560966.

Antibody Name: Rabbit Anti-Human Her2 / ErbB2 Monoclonal Antibody, Unconjugated, Clone 29D8

Description: This monoclonal targets Human Her2 / ErbB2

Target Organism: human

Clone ID: Clone 29D8

Antibody ID: AB_10692490

Vendor: Cell Signaling Technology

Catalog Number: 2165

Record Creation Time: 20250820T024948+0000

Record Last Update: 20250820T143738+0000

Ratings and Alerts

No rating or validation information has been found for Rabbit Anti-Human Her2 / ErbB2 Monoclonal Antibody, Unconjugated, Clone 29D8.

No alerts have been found for Rabbit Anti-Human Her2 / ErbB2 Monoclonal Antibody, Unconjugated, Clone 29D8.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 56 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Cheng X, et al. (2026) Interleukin-34-Induced Arg1+ Macrophages Play a Key Role in Breast Cancer Brain Metastasis. Cancer research communications, 6(6), 1388.

Rampa DR, et al. (2026) Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(8), 1454.

Burke CM, et al. (2026) Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression. Molecular cancer therapeutics, 25(1), 156.

Kang M, et al. (2026) Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells. Molecular cancer therapeutics, 25(5), 814.

Ma K, et al. (2026) ErbB family receptor dimerization dynamics and dysregulation via long-term single-molecule imaging. Cell, 189(11), 3413.

Rao X, et al. (2026) Paired patient-derived organoids reveal transcription factor-driven epigenetic remodeling in breast cancer metastasis. Cell stem cell, 33(4), 622.

Fu Z, et al. (2026) Integrative proteogenomic analysis provides molecular insights and clinical significance in gallbladder cancer. Cancer cell.

Lam D, et al. (2026) Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function. Cancers, 18(3).

Garg SK, et al. (2026) Potentiating dendritic cell immunotherapy by interrupting the Semaphorin 4D-induced immune-suppressive barrier. Cell reports, 45(3), 117050.

Theardy MS, et al. (2025) Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers. Cell reports. Medicine, 6(8), 102253.

Conticelli D, et al. (2025) AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer. Cancer research, 85(16), 3111.

Liao CY, et al. (2025) CD3xHER2 bsAb-Mediated Activation of Resting T-cells at HER2 Positive Tumor Clusters Is Sufficient to Trigger Bystander Eradication of Distant HER2 Negative Clusters Through IFN γ and TNF α . *European journal of immunology*, 55(4), e202451589.

Abdulkareem NM, et al. (2025) Interactions between ADGRF1 (GPR110) and extracellular matrix proteins govern its effects on tumorigenesis in HER2-positive breast cancer. *British journal of pharmacology*, 182(11), 2524.

Deng T, et al. (2025) CINTER-seq: Chemical profiling reveals interaction-dependent cell landscapes and gene signatures in vivo. *Immunity*, 58(9), 2336.

Pataccini G, et al. (2025) Steroid hormone receptors, exome sequencing and treatment responsiveness of breast cancer patient-derived xenografts originated in a South American country. *Scientific reports*, 15(1), 2415.

Xia Z, et al. (2025) circADAMTS12 Inhibits the Antitumor Activity of Microglia to Enable Metastatic Colonization in the Brain. *Cancer research*, 85(24), 4977.

Chen W, et al. (2025) Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding. *Cancer discovery*.

House NC, et al. (2025) CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. *NPJ breast cancer*, 11(1), 135.

Trekitkarnmongkol W, et al. (2024) Epigenetic activation of SOX11 is associated with recurrence and progression of ductal carcinoma in situ to invasive breast cancer. *British journal of cancer*, 131(1), 171.

Liao CY, et al. (2024) CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing. *Communications biology*, 7(1), 983.